Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics

Nephrology Dialysis Transplantation

Volumn 16, Issue SUPPL. 1, 2001, Pages 85-89

  Lozano, Jose V ^a   Llisterri, Jose L ^b   Aznar, J ^c   Redon, Josep ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL MARINA ALTA   (Spain)

Author keywords

Diabetes; Hypertension; Losartan; Microalbuminuria

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LOSARTAN; TRIACYLGLYCEROL; URIC ACID;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; METABOLIC REGULATION; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RENAL SYSTEM PARAMETERS; SITTING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 0035001592     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.suppl_1.85     Document Type: Article

References (21)

1. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association
2. Diabetes mellitus and hypertension
3. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications
4. Hypertension in diabetes study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients
5. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes
6. Diabetic nephropathy
7. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
9. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
10. Reduction in albuminuria predicts diminished progression in diabetic nephropathy
11. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
12. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
13. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
14. Captopril or conventional therapy in hypertensive type II diabetics: Three-year analysis
15. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
16. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin
17. British Hypertension Society. Recommendations on blood pressure measurement
18. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis
19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33
20. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy
21. The role of vasoactive compounds, growth factors and cytokines in the progression of renal diseases